Non-Small Cell Lung Cancer (NSCLC)

>

Latest News

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.
EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors

November 20th 2024

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.
Subcutaneous Pembrolizumab/Chemo Meets Pharmacokinetic Endpoints in NSCLC

November 20th 2024

FoundationOne Liquid CDx has been approved as a diagnostic tool for tepotinib in patients with non–small cell lung cancer METex14 skipping alterations.
FDA Approves FoundationOne Liquid CDx as Diagnostic Tool for NSCLC

November 19th 2024

Precision Medicine in NSCLC The Power of Molecular Testing
Precision Medicine in NSCLC The Power of Molecular Testing

November 13th 2024

Data from TROPION-Lung05, TROPION-Lung01, and TROPION-PanTumor01 support the new BLA for dato-DXd in advanced or metastatic EGFR-mutated NSCLC.
FDA Receives New BLA for Dato-DXd in Advanced EGFR+ NSCLC

November 12th 2024